Pediair Drug Interactions

Interactions with Other Medicaments: Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma and in the treatment of allergic rhinitis.
Since montelukast is metabolised by CYP 3A4, caution should be exercised, particularly in children, when montelukast is co-administered with enzyme inducers of CYP 3A4, such as phenytoin, phenobarbital and rifampicin.
Concurrent use of montelukast and phenobarbital may result in decreased bioavailability of montelukast.
Concurrent use of montelukast and rifampicin may result in decreased bioavailability of montelukast.
Montelukast is a potent inhibitor of CYP 2C8. Montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide.)
Concurrent use of gemfibrozil and montelukast may result in elevated montelukast plasma concentrations.
Concurrent use of prednisone and montelukast may result in severe peripheral edema.
Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.